Precision Health Clinical Trials

Cystoscopic Evaluation Predicting pT0 Urothelial Carcinoma of the Bladder

Condition:   Urothelial Carcinoma
Intervention:   Procedure: Radical Cystectomy
Sponsors:   Fox Chase Cancer Center;   Temple University
Recruiting

Gait as Predictor of Dementia and Falls. The Gait and Brain Cohort Study

Conditions:   Gait Apraxia;   Mild Cognitive Impairment;   Subjective Cognitive Impairment;   Cerebral Atrophy;   Alzheimer Disease;   Dementia
Intervention:  
Sponsor:   Lawson Health Research Institute
Recruiting

Heart Attack Research Program: Platelet Sub-Study (HARP)

Condition:   Myocardial Infarction
Intervention:  
Sponsor:   NYU Langone Health
Recruiting

Scrub Typhus Antibiotic Resistance Trial

Condition:   Scrub Typhus
Interventions:   Drug: Doxycycline 7 days;   Drug: Doxycycline 3 days;   Drug: Azithromycin 3 days
Sponsors:   University of Oxford;   Shoklo Malaria Research Unit;   Chiangrai Prachanukroh Hospital
Recruiting

Genetic and Epigenetic Determinants of Response to Fluorouracil-based Adjuvant Chemotherapy in Patients With Stage III Colorectal Cancer

Condition:   Stage III Colorectal Cancer
Interventions:   Genetic: Gene mutations analysis;   Genetic: Gene methylation analysis;   Genetic: Gene expression analysis;   Genetic: SNP analysis;   Genetic: Protein expression analysis
Sponsor:   Renmin Hospital of Wuhan University
Not yet recruiting

Analysis of DNA Methylation in Spondyloarthritis

Conditions:   Spondylitis, Ankylosing;   Axial Spondyloarthritis;   DNA Methylation
Intervention:   Other: Blood sample
Sponsor:   Centre Hospitalier Universitaire de Besancon
Recruiting

The Epigenetic Modification in OPRM1 on Postoperative Analgesia and Side Effect Induced by Sufentanil

Condition:   Epigenetics
Interventions:   Drug: Sufentanil;   Drug: dexmedetomidine;   Drug: propofol;   Drug: Rocuronium;   Drug: sevoflurane;   Drug: remifentanil;   Drug: Parecoxib
Sponsor:   Huazhong University of Science and Technology
Recruiting

Two Cancers, One Gene. Why Some People in Families Develop Melanoma or Pancreas Cancer, While Still Others Never Develop Cancer.

Conditions:   Pancreas Cancer;   Melanoma
Intervention:  
Sponsors:   Mayo Clinic;   National Cancer Institute (NCI)
Recruiting

Ensartinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With ALK or ROS1 Genomic Alterations (A Pediatric MATCH Treatment Trial)

Conditions:   Advanced Malignant Solid Neoplasm;   Malignant Solid Neoplasm;   Recurrent Ependymoma;   Recurrent Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor;   Recurrent Hepatoblastoma;   Recurrent Langerhans Cell Histiocytosis;   Recurrent Malignant Germ Cell Tumor;   Recurrent Malignant Glioma;   Recurrent Malignant Solid Neoplasm;   Recurrent Medulloblastoma;   Recurrent Neuroblastoma;   Recurrent Non-Hodgkin Lymphoma;   Recurrent Osteosarcoma;   Recurrent Primary Central Nervous System Neoplasm;   Recurrent Rhabdoid Tumor;   Recurrent Rhabdomyosarcoma;   Recurrent Soft Tissue Sarcoma;   Refractory Ependymoma;   Refractory Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor;   Refractory Hepatoblastoma;   Refractory Langerhans Cell Histiocytosis;   Refractory Malignant Germ Cell Tumor;   Refractory Malignant Glioma;   Refractory Malignant Solid Neoplasm;   Refractory Medulloblastoma;   Refractory Neuroblastoma;   Refractory Non-Hodgkin Lymphoma;   Refractory Osteosarcoma;   Refractory Primary Central Nervous System Neoplasm;   Refractory Rhabdoid Tumor;   Refractory Rhabdomyosarcoma;   Refractory Soft Tissue Sarcoma;   Wilms Tumor
Interventions:   Procedure: Biospecimen Collection;   Procedure: Bone Marrow Aspiration and Biopsy;   Procedure: Bone Scan;   Procedure: Computed Tomography;   Drug: Ensartinib;   Other: Laboratory Biomarker Analysis;   Procedure: Magnetic Resonance Imaging;   Other: Pharmacological Study;   Procedure: Positron Emission Tomography;   Procedure: Radionuclide Imaging;   Procedure: X-Ray Imaging
Sponsors:   National Cancer Institute (NCI);   Children's Oncology Group
Recruiting

Olaparib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With Defects in DNA Damage Repair Genes (A Pediatric MATCH Treatment Trial)

Conditions:   Advanced Malignant Solid Neoplasm;   Ann Arbor Stage III Childhood Non-Hodgkin Lymphoma;   Ann Arbor Stage IV Childhood Non-Hodgkin Lymphoma;   Low Grade Glioma;   Malignant Glioma;   Recurrent Childhood Central Nervous System Neoplasm;   Recurrent Childhood Ependymoma;   Recurrent Childhood Malignant Germ Cell Tumor;   Recurrent Childhood Non-Hodgkin Lymphoma;   Recurrent Childhood Rhabdomyosarcoma;   Recurrent Childhood Soft Tissue Sarcoma;   Recurrent Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor;   Recurrent Glioma;   Recurrent Hepatoblastoma;   Recurrent Langerhans Cell Histiocytosis;   Recurrent Malignant Solid Neoplasm;   Recurrent Medulloblastoma;   Recurrent Neuroblastoma;   Recurrent Osteosarcoma;   Refractory Childhood Malignant Germ Cell Tumor;   Refractory Ependymoma;   Refractory Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor;   Refractory Glioma;   Refractory Hepatoblastoma;   Refractory Langerhans Cell Histiocytosis;   Refractory Malignant Glioma;   Refractory Malignant Solid Neoplasm;   Refractory Medulloblastoma;   Refractory Neuroblastoma;   Refractory Non-Hodgkin Lymphoma;   Refractory Osteosarcoma;   Refractory Primary Central Nervous System Neoplasm;   Refractory Rhabdomyosarcoma;   Refractory Soft Tissue Sarcoma;   Rhabdoid Tumor;   Wilms Tumor
Intervention:   Drug: Olaparib
Sponsor:   National Cancer Institute (NCI)
Recruiting

Pages